Evidence map›Paper›PMID 38148483›Full record

ArticleOral diseases2024

The minimally important difference for the Xerostomia Inventory among Sjögren's disease patients.

Zainab Assy, William Murray Thomson, Henk S Brand, Seunghee Cha, Merve M Susam, Gary A Weisman, Arjan Vissink, Floris J Bikker, Derk Hendrik Jan Jager

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zainab AssyDepartment of Oral Biochemistry, Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-1531-8930
William Murray ThomsonSir John Walsh Research Institute, University of Otago Faculty of Dentistry, Dunedin, New Zealand.ORCID 0000-0003-0588-6843
Henk S BrandDepartment of Oral Biochemistry, Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands.
Seunghee ChaDepartment of Oral and Maxillofacial Diagnostic Sciences, Center for Orphaned Autoimmune Disorders, University of Florida, Gainesville, Florida, USA.
Merve M SusamDepartment of Clinical Pharmacology and Pharmacy, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-2288-6984
Gary A WeismanDepartment of Biochemistry, Christopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.ORCID 0000-0002-3246-6353
Arjan VissinkDepartment of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-2581-4361
Floris J BikkerDepartment of Oral Biochemistry, Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-9453-4630
Derk Hendrik Jan JagerDepartment of Oral and Maxillofacial Surgery/Oral Pathology, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-3006-2128

Funding

Phase I/IIa Clinical Trial Using Localized and Systemic Delivery of the P2X7 Receptor Antagonist AZD9056 for the Treatment of Salivary Gland Dysfunction in Sjögren's Syndrome PatientsR34AI155318 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI VISSINK, ARJAN, WEISMAN, GARY ANDREW · 2022 to 2022
$202k
NIAID NIH HHS R34 AI155318
6 · The paper itself

Abstract

objectiveUntil now, the clinically relevant improvement for the Xerostomia Inventory (XI) has not been defined. Therefore, our aim was to determine the Minimally Important Difference (MID) of the XI for improvement in dry-mouth symptoms in SjD patients.

methodThe study recruited 34 SjD patients who underwent sialendoscopy of major salivary glands and 15 SjD patients in a nonintervention control group. XI scores were assessed at several time points. The MID was determined from the mean difference in XI scores between the groups with and without improvement.

resultsIn the control group, no significant XI score changes were seen. In the sialendoscopy group, a clinically relevant XI score change of four scale points was identified after 1 week. For a prolonged duration (≥16 weeks), a minimum reduction of seven scale points in the XI score was required to indicate clinically relevant improvement.

conclusionIn SjD patients, a minimum change of four points in the XI score indicates a clinically relevant improvement for evaluating short-term effects. For prolonged effects, a clinically relevant improvement requires a MID of seven points. The determination of the MID in XI could assist in future studies that evaluate changes in xerostomia.

Indexed as

Sjogren's SyndromeXerostomiaAdultAgedCase-Control StudiesEndoscopyFemaleHumansMaleMiddle AgedMinimal Clinically Important Differenceclinical trialsendpoint determinationpatient reported outcome measuresSjögren's syndromexerostomiaXerostomia Inventory

Identifiers

PMID38148483
PMCPMC11199375

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.